ResMed (RMD) Stock Price, News & Analysis

+3.21 (+1.78%)
(As of 12:34 PM ET)
Today's Range
50-Day Range
52-Week Range
456,188 shs
Average Volume
1.00 million shs
Market Capitalization
$27.00 billion
P/E Ratio
Dividend Yield
Price Target

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
8.7% Upside
$199.20 Price Target
Short Interest
5.36% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.73mentions of ResMed in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.05 M Sold Last Quarter
Proj. Earnings Growth
From $7.47 to $8.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

35th out of 910 stocks

Surgical & Medical Instruments Industry

6th out of 95 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

Reviewing ResMed (NYSE:RMD) and Orthofix Medical (NASDAQ:OFIX)
ResMed (RMD) Set to Announce Earnings on Thursday
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
ResMed Unusual Options Activity For April 17
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
ResMed: Not A Sleeper
ResMed Inc Director Peter Farrell Sells 23,535 Shares
Resmed Inc.
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 3/14 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$897.56 million
Pretax Margin


Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.88 per share
Book Value
$28.11 per share


Free Float
Market Cap
$26.53 billion

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained


Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. has been consistently introducing innovative medical devices and cloud-based software applications, staying ahead in the healthcare technology sector.
  • The company's focus on respiratory care and software as a service segments aligns with the growing demand for remote patient monitoring and digital health solutions.
  • ResMed's recent stock price performance has shown positive momentum, indicating investor confidence and potential for capital appreciation.
  • ResMed's diverse product portfolio catering to various respiratory disorders provides a competitive edge in the market and potential for revenue growth.
  • The company's strategic partnerships and acquisitions enhance its market presence and offer opportunities for expansion into new healthcare segments.


Investors should be bearish about investing in ResMed Inc. for these reasons:

  • ResMed Inc. operates in a highly competitive industry with evolving regulations and technological advancements, leading to potential challenges in maintaining market share.
  • The company's reliance on continuous innovation and product development may pose risks of regulatory hurdles, delays, or product recalls affecting financial performance.
  • Fluctuations in healthcare policies and reimbursement rates could impact ResMed's revenue streams and profitability, adding uncertainty to investment returns.
  • Global economic conditions and geopolitical factors may influence ResMed's international operations and expose the company to currency exchange risks.
  • Investors should consider the cyclicality of the healthcare sector, which could affect ResMed's financial results and stock performance during economic downturns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 brokers have issued 12-month price objectives for ResMed's shares. Their RMD share price targets range from $165.00 to $230.00. On average, they predict the company's stock price to reach $199.20 in the next year. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 at the beginning of the year. Since then, RMD stock has increased by 6.5% and is now trading at $183.27.
View the best growth stocks for 2024 here

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our RMD earnings forecast

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13745785".

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Wednesday, January, 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.81 by $0.07. The medical equipment provider had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.15 billion. ResMed had a trailing twelve-month return on equity of 23.86% and a net margin of 19.77%. The company's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.66 earnings per share.
Read the conference call transcript

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, January 24th. Investors of record on Thursday, February 8th will be given a dividend of $0.48 per share on Thursday, March 14th. This represents a $1.92 annualized dividend and a yield of 1.05%. The ex-dividend date of this dividend is Wednesday, February 7th.
Read our dividend analysis for RMD

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.07%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.19% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.40%), Los Angeles Capital Management LLC (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Confluence Investment Management LLC (0.09%), ST Germain D J Co. Inc. (0.07%) and Synergy Asset Management LLC (0.05%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi and Robert Andrew Douglas.
View institutional ownership trends

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners